ReviewKidney medicine2025
Autophagy in the Pathogenesis of Membranous Nephropathy.
Review in Kidney medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Membrane atg8ylation and autophagy in protection against Mycobacterium tuberculosis.Journal of immunology (Baltimore, Md. : 1950) · 2026Review
- Programmed Cell Death: A Key Mechanism of Traditional Chinese Medicine in the Treatment of Membranous Nephropathy.Drug design, development and therapy · 2026Review
- The effects of traditional Chinese botanical medicine on membranous nephropathy.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Membranous nephropathy (MN) is a leading cause of nephrotic syndrome in adults. In most cases, its etiology is unknown (idiopathic), while ∼30% of cases are secondary to other diseases, infections, or exposure to drugs and toxic agents. Up to 70% of patients with idiopathic MN have circulating antibodies against the M-type phospholipase A2 receptor, a podocyte surface protein. The formation of immune complexes on podocytes triggers complement activation, leading to the activation of both the C5b-C9 complex and C5a. Recently, several novel podocyte antigens have been identified in both idiopathic and secondary MN. Autophagy, a cellular mechanism that removes and recycles damaged cytoplasmic material, may have a dual role in MN pathogenesis. It can regulate innate and adaptive immune responses, promoting the production of autoantibodies against podocyte antigens. However, autophagy also protects podocytes from apoptosis and injury. In addition, it plays a role in the progression of tubular atrophy and interstitial fibrosis, which can lead to chronic kidney disease and kidney failure. This article explores the mechanisms that activate and regulate macroautophagy and examines its role in MN. The potential therapeutic implications of autophagy regulation in MN, based on preliminary studies, are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.